Relationship between KLF5 copy number and gene expression in different tumor types. In gastrointestinal tumors with predominantly KLF5 amplification, including gastric cancer (STAD), colon cancer (COAD), and rectum cancer (READ), an increase in KLF5 transcripts could be observed (top 3 figures). For prostate cancer (PRAD), kidney chromophobe (KICH), and testicular germ cell tumors (TGCT), KLF5 deletion is predominant, and a decrease in KLF5 transcription could be observed (middle 3 figures). For other tumor types such as esophageal carcinoma (ESCA), bladder urothelial carcinoma (BLCA) and uterine corpus endometrial carcinoma (UCEC), which have comparable rates of KLF5 amplification and deletion, KLF5 copy number changes and gene expression shows a dose-response relationship (bottom 3 figures). * 0.05 < p < 1 × 10−4, ** 1 × 10−4 < p < 1 × 10−6, *** p < 1 × 10−6.